e-Connect Logo
Issue:  January 2012 •  Archive  •  Subscribe •  Unsubscribe
In This Edition Featured Article Featured CE
•  Editor's Notebook
•  Counseling Pearls
•  It's the Law
•  Clinical Corner
•  Consult Your Pharmacist
•  Educational Spotlight
•  Quick Poll
      –Type 2 Diabetes
  Photo Bell's Palsy: To Treat or Not to Treat
Because of the high rate of spontaneous recovery, some experts question the use of pharmacologic agents.
  Photo Deep Brain Stimulation Surgery for Parkinson's Disease
This procedure can improve symptoms of tremor, rigidity, bradykinesia, and dyskinesia.

NEW! Follow us on
Fb Logo  Tw Logo

Editor's Notebook
It's Not Only About the Money

Medication cost is not the only factor that contributes to poor compliance and adherence.
Counseling Pearls
Photo GERD-Related Sleep Disturbances

Nighttime heartburn occurs in a large number of patients with gastroesophageal reflux disease (GERD), and nocturnal heartburn and GERD impair sleep and impact daily functioning.
Photo Multiple Sclerosis Treatment Update

Goals of treatment include decreasing symptoms, prevention or attenuation of lesion progression, and reducing long-term disabilities. Research is focused on disease-modifying therapies.
It's the Law
The (Non) Law of Drug Shortages

Many factors contribute to why reported drug shortages are at their highest levels in more than a decade.
 
Clinical Corner
Photo Neurologic Complications of HIV

Despite the availability of effective antiretroviral therapy, more than 25% of people with HIV infection will develop neurologic disorders. These disorders range from minor deterioration in motor and information-processing speed to severely incapacitating symptoms that affect the patient's functional capacity.
Photo Botulinum Toxin for the Treatment of Movement Disorders

Movement disorders secondary to central nervous system disease and skeletal-muscle overactivity can be extremely debilitating. Clinical applications of this neurotoxin include cerebral palsy, multiple sclerosis, and Parkinson's disease.
 

Advertisement

 
Consult Your Pharmacist
Insomnia and Snoring

One-fourth of Americans experience occasional problems sleeping.
Educational Spotlight
Clinical Considerations for the Treatment of H pylori Infection

It is important to develop individualized treatment regimens for afflicted patients.
Drug Treatment of Addictive Diseases

Without intervention, drug and alcohol addiction is a chronic and potentially fatal disease.
 
Newswire
Nicotine Patch May Help Improve Memory
Nashville, TN — According to a recent study published in Neurology, people with mild cognitive impairment may benefit from the use of a transdermal nicotine patch. The study involved 74 people with an average age of 76 years who had mild cognitive impairment and were not smokers. Half of the participants received a nicotine patch of 15 mg per day and half received a placebo. After 6 months of treatment, the nicotine-treated group regained 46% of normal performance for age on long-term memory, whereas the placebo group worsened by 26%. “This study provides strong justification for further research into the use of nicotine for people with early signs of memory loss,” said researcher Paul Newhouse, MD, of Vanderbilt University School of Medicine in Nashville.
Mild Flu Season Expected
Atlanta, GA — The CDC reports that there has been low influenza activity across the United States so far this winter. Flu incidence was deemed “minimal” across 48 states, with just 1.4% of outpatient visits attributed to the flu, down from the seasonal average of 2.4%. As of January 1, 2012, there were no reported cases of children dying from the flu. The strains being seen this year are not particularly virulent and seem well-matched with this season's vaccine. “Vaccination continues to be the single-most important thing people can do to protect themselves from flu,” said Tom Skinner, CDC spokesperson.
Alzheimer's Drug Development Suspended
New York, NY— Following disappointing phase III trial results, development of the experimental Alzheimer's medication Dimebon (latrepirdine) has been halted by Pfizer Inc. and partner Medivation Inc. The drug, originally an antihistamine used in Russia, showed no statistically significant benefit over placebo in patients with mild-to-moderate Alzheimer's disease. In the phase III CONCERT study, the addition of Dimebon to ongoing treatment with Aricept (donepezil) failed to meet the two co-primary endpoints—change from baseline in the Alzheimer's Disease Assessment Scale–cognitive subscale (ADAS-cog) or the activities of daily living subscale (ADAS-ADL). The companies will be terminating their agreement to develop and market the drug.
To subscribe to e-Connect, send your name, address, and email address to us by clicking here. U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.